FTSE MIB
34.171,18 +231,43 (+0,68%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,77 +0,20 (+0,24%) Bitcoin EUR
59.909,30 +531,79 (+0,90%)
Avid Bioservices, Inc. (CDMO)
Dopo ore:
| Chiusura precedente | 6,83 |
| Aperto | 6,74 |
| Denaro | 7,30 x 200 |
| Lettera | 7,36 x 100 |
| Min-Max giorno | 6,71 - 7,40 |
| Intervallo di 52 settimane | 4,07 - 18,86 |
| Volume | |
| Media Volume | 1.353.193 |
| Capitalizzazione | 464,672M |
| Beta (5 anni mensile) | 1,62 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,28 |
| Prossima data utili | 29 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,25 |
GlobeNewswireAvid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference
TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Capital Markets Virtual CDMO Conference. Nick Green, president and chief executive officer, will be the featured speaker in
- GlobeNewswire
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023
-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains on Schedule for Opening by End of Calendar Q3 2023 -- TUSTIN, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manu
- GlobeNewswire
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2024 on September 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members
